Results 161 to 170 of about 48,812 (228)

Cardiovascular Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Case Reports. [PDF]

Cancer Rep (Hoboken)
Godin SL, Kingma T, Pillai A, Kholoki O, Kim AS.   +4 more
europepmc   +1 more source

Case Report: Neuroretinitis following combination checkpoint inhibition therapy with nivolumab and ipilimumab for stage IIIC melanoma. [PDF]

Front Oncol
Arefin NS, Moon J, Roller AB, Aung MH.
europepmc   +1 more source

Severe Multisystem Toxicity from Combination Ipilimumab and Nivolumab in Metastatic Melanoma: A Case Report. [PDF]

J Community Hosp Intern Med Perspect
Amer B, Manerkar S.
europepmc   +1 more source

Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma. [PDF]

J Immunother Cancer
McKay RR, Serzan M, Xie W, McGregor BA, Braun D, Wei X, Kyriakopoulos C, Zakharia Y, Maughan BL, Rose T, Stadler WM, Mcdermott DF, Choueiri TK.   +12 more
europepmc   +1 more source

Correction: Iinuma et al. Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. <i>J. Clin. Med.</i> 2021, <i>10</i>, 5325. [PDF]

J Clin Med
Iinuma K, Enomoto T, Kawada K, Fujimoto S, Ishida T, Takagi K, Nagai S, Ito H, Kawase M, Nakai C, Kawase K, Kato D, Takai M, Nakane K, Kameyama K, Koie T.   +15 more
europepmc   +1 more source

Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial. [PDF]

J Immunother Cancer
Eefsen RL, Spindler NJ, Theile S, Al-Farra G, Hendel HW, Lorentzen T, Fredberg Persson G, Behrens CP, Chen IM, Madsen K, Sengeløv L, Svane IM, Lindberg H, Kongsted P, Nielsen DL.   +14 more
europepmc   +1 more source

Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab. [PDF]

Int J Urol
Numakura K, Abe N.
europepmc   +1 more source

Immune-Related Adverse Events and Therapeutic Outcomes After Stopping Immune Checkpoint Inhibitors due to Toxicity Among Patients With Metastatic Melanoma (University Hospitals Sussex). [PDF]

Cancer Med
Iessa K, Kantilal K, Garekyaragh I, Paget L, Mangan Y, Shamsaldeen YA.   +5 more
europepmc   +1 more source

Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti-CTLA-4 in Melanoma with Primary Resistance to Anti-PD-1. [PDF]

Cancer Discov
Campbell KM, Chen DG, Bustami ZE, Naser Al Deen N, Medina E, Gonzalez CR, Maxey J, Thompson MA, Samorodnitsky S, Kuklinski LF, Perez Garcilazo I, Baselga-Carretero I, Vega-Crespo A, Chen JM, Elumalai R, Visitacion M, Schiemann R, Padron L, Chang C, Zelin AE, Chelluri SS, Boffo S, Kendra KL, Chmielowski B, Truong TG, Khushalani NI, Collichio F, Ikeguchi AP, Victor AI, Margolin KA, Johnson DB, Chen Y, Sosman JA, Patel SP, Hu-Lieskovan S, Moon J, Wells DK, Spencer CN, Bellasea S, Vanderwalde AM, Wu MC, Scumpia PO, Ribas A.   +42 more
europepmc   +1 more source

Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database. [PDF]

Front Oncol
Yang Y, Wang F, Tong W, Lu X, Zhao F, Fang S, Wang S.   +6 more
europepmc   +1 more source